Enlitic, Inc. to Showcase AI Enabled Workflows at ViVE 2025
Highlights
Location: Nashville Music City Center, Nashville, TN
Enlitic Booth: 2308
FORT COLLINS, Colo., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Enlitic, Inc. will demonstrate its latest version of data standardization software, Ensight™ 2.0 offering:
Standardized study and series descriptions generation
Protected Health Information (PHI) deidentification
Enhanced radiologist reporting workflows
Improved data quality
New revenue opportunities for healthcare providers
Michael Sistenich, CEO of Enlitic, stated, 'We are excited to present our cutting-edge ai enabled workflow and data migration solutions at ViVE 2025. Our participation underscores our commitment to addressing the long-standing challenges in healthcare data utilization and contributing to better outcomes for our customers.'
A highlight of Enlitic's presence at ViVE 2025 will be ENABLE, Enlitic's newest offering innovative search and cohort development modules. These new additions to Enlitic's product lineup promise to further revolutionize the field of radiology AI.
The recent acquisition of Laitek has enabled the two companies to combine forces and deliver AI enabled data migration that promises to greatly reduce the time required to migrate DICOM studies while vastly improving the data quality. Combined with Enlitic's ENDEX data standardization, data migration takes on a whole new perspective as data quality becomes a key differentiator.
About Enlitic
At Enlitic, we empower healthcare systems to enhance the quality of their medical imaging data using the capabilities of artificial intelligence. Enlitic has developed an intelligent data framework that powers radiology workflows, orchestrates data between systems, and enables greater comprehension of what information resides in archives thereby unlocking new revenue opportunities, generating cost-savings, and improving healthcare delivery. Enlitic enables providers to realize value from decades of stored data.
Contact:
Enlitic Media Relations
David Wilson
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
XPENG Announces New G6 and G9 Ultra Smart SUVs for Europe
Redefining Performance, Design, and Intelligent Technology for the Next Generation of Electric Vehicles. Powered by Industry-Leading Powertrain Technology: 5C Supercharging Battery and 800V High-voltage SiC Platform across all trims. Charging Speed 12 minutes 10-80% SOC placing it at the forefront of the EV revolution. Smart Comfort Meets All-New Interior and Cockpit Upgrades. Expressive New Colors Inside and Out, adding individuality and Appeal. AMSTERDAM, June 12, 2025 (GLOBE NEWSWIRE) -- XPENG, a leading global smart electric vehicle (EV) manufacturer driven by innovation and advanced AI technology, is proud to unveil the new versions of its Ultra Smart Coupe SUV XPENG G6 and Ultra Smart Premium SUV XPENG G9 for the European market. Both models have been upgraded inside and out and feature XPENG's next-gen full-domain 800V high-voltage SiC platform alongside a 5C supercharging battery. This enables ultra-fast charging up to 525 kW for the new XPENG G9 and 451kW for the new XPENG G6, leading in their class. The new XPENG G6, featuring a complete overhaul and a new color Stellar Purple, will be on static display at Le Mans Village in France starting today. European customers can now register their interest for both models via XPENG's official websites in the Netherlands, Belux, Norway, Denmark, Sweden, Germany, and France. Order will open from XPENG G6 and G9 The Heart of Innovation: The Supercharging Battery Upgraded from 3C to 5C At the core of the new XPENG G6 and G9 is an industry-first upgrade to 5C lithium iron phosphate (LFP) batteries for all trims. This next-gen battery technology offers a safer, more eco-friendly solution by eliminateing the need for resource-intensive and costly minerals such as cobalt and nickel, making the version more sustainable without compromising performance. Both models are equipped with XPENG's industry-leading powertrain technology, including the 5C Supercharging Battery and a full-domain 800V high-voltage SiC platform, available across all trims. The result is exceptional charging speed with a 10-80% State of Charge (SOC) achieved in just 12 minutes, setting new benchmarks. XPENG continues to lead in intelligent driving technology. The new XPENG G6 and G9 features a full upgraded intelligent driving suite, including a MicroFiber capacitance steering wheel, advanced driving chip and single-pixel Lofic architecture for accurate, clearer and longer-range perception for enhanced safety and control. Complementing the driving experience is an upgraded cockpit powered by a high-performance cockpit chip and support for Apple CarPlay & Android Auto as standard, ensuring a smarter, smoother and more joyful 800V High-voltage SiC Platform Revolutionary Design Enhancements The new XPENG G6 is as much about style as it is about substance. The exterior is defined by the all-new 1942 mm full-width Starlight Wing LED light bar, integrated turn signals, and a redesigned rear diffuser for a cleaner finish. The new XPENG G6 Stellar Purple features a low-saturation neutral purple tone with metallic flakes infused into the paint, creating a gradient effect shifting from deep purple to light purple under changing light. Its matte metallic finish glimmers subtly like starlight in the sun, blending a sense of mystery with technology. When paired with the new XPENG G6's streamlined coupe-SUV body, it exudes both elegance and sporty dynamism, setting a benchmark for color aesthetics in the smart mobility XPENG G6 The new XPENG G9 Black Edition delivers an equality captivating presence, dressed in a deep midnight black paint paired with blackened wheels, logos, and fender decorations. The fiery orange brake calipers create a striking visual contrast, adding a mysterious yet sharp XPENG G9 Inside, the new XPENG G6 boasts a completely re-imagined interior that focuses on premium materials, immersive technology, and comfort. The new Super Star-Ring Interior Design has transformed 60% of the cabin, introducing a sleek new dashboard, ambient lighting, and a new capacitive steering wheel. Premium materials and immersive design define the cabin with refined color themes - Dark Gray and Light Gray - enhancing the ultra-modern ambiance. Both the new XPENG G6 and G9 have received significant upgrades in comfort and smart functionality. New XPENG G6: Front seats feature a massage function with lumbar support, delivering refined comfort for both driver and passenger. New XPENG G9: A luxury comfort upgrade featuring an ultra-large three-layer heat-insulating panoramic sunroof, luxurious comfort seats with 10-point XPENG G6 InteriorNew XPENG G9 Interior About XPENG Founded in 2014, XPENG is a leading Chinese AI mobility company that designs, develops, manufactures, and markets intelligent electric vehicles, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to lead the intelligent electric vehicle revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG in-house develops its advanced driver assistance technology (ADAS) and intelligent in-car operating system, along with core vehicle systems such as powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its intelligent electric vehicles are mainly produced at its plants in Zhaoqing and Guangzhou, Guangdong Province. XPENG is listed on the New York Stock Exchange (NYSE: XPEV) and the Hong Kong Stock Exchange (HKEX: 9868). For more information, visit Contacts: For Media Enquiries: XPENG PR Department Email: pr@ Photos accompanying this announcement are available at in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
PCR (qPCR, dPCR, Singleplex, Multiplex) Market Research Report 2025-2030 with Situation Analysis, Executives and Marketing Guide, & Investment Analysts and Management Consultants Guide
Explore the evolving PCR technology landscape with our comprehensive report. Discover market trends, including Singleplex and Multiplex testing, and the impact of digital PCR. Uncover investment opportunities in Point of Care Testing and Molecular Diagnostics. Gain insights with five-year forecasts and expert analysis. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "PCR Markets: Forecasts for qPCR, dPCR, Singleplex & Multiplex Markets and by Application, Product and Place Forecasting and Analysis" has been added to offering. This report provides comprehensive insights into how this convergence will shape future market dynamics, presenting critical information for industry stakeholders. The global landscape of disease diagnosis is undergoing a significant transformation, with PCR technology at its forefront. While the pandemic elevated PCR to a dominant position, ushering in a digital revolution within the sector, new markets and technologies are now emerging that may redefine diagnostics. This transition presents both opportunities and challenges for stakeholders. A newly released report offers an in-depth analysis of the market, featuring a five-year forecast that is uniquely segmented into Singleplex and Multiplex testing markets. PCR, which has showcased remarkable adaptability, gained widespread recognition as an essential tool in diagnostics. The advent of digital PCR further promises to enhance its efficacy, offering reduced costs and improved patient outcomes. Moreover, digital PCR stands as a powerful contender in combating Anti Microbial Resistance. For professionals seeking to leverage this data, the report is an indispensable resource that can transform executives into industry experts. It enables informed investment decisions and accurate company valuations, backed by the most current data available. With its detailed five-year market forecasts, the report equips organizations with the tools needed to strategically navigate this evolving landscape. In a market driven by innovation, understanding the nuances of these emerging technologies and their implications is crucial. This report encapsulates the trends, challenges, and opportunities that define the future of PCR technologies and diagnostics. Stay ahead of the curve by accessing the latest findings that will keep PCR at the core of disease detection and management globally. Discover how emerging diagnostics technology and market innovations are reshaping the competitive landscape. Access the full report today to explore untapped potential and prepare for the future of healthcare. Key Topics Covered: 1 Market Guides1.1 Situation Analysis1.2 Guide for Executives and Marketing Staff1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition2.1 What are PCR Technologies?2.2 PCR and Syndromic Testing2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry2.5.1 Global Healthcare Spending2.5.2 Spending on Diagnostics2.5.3 Important Role of Insurance for Diagnostics 3 PCR - Guide to PCR Technologies3.1 Concepts3.1.1 Method3.2 Applications3.2.1 Finding Specific DNA3.2.2 Measuring DNA3.2.3 Medical and Diagnostic Applications3.2.3.1 Carrier, prenatal and tissue typing3.2.3.2 Cancer Diagnosis and Management3.2.3.3 Infectious Disease - New Levels of Accuracy and Sensitivity3.2.3.4 Forensic Applications3.2.3.5 Science and Research3.3 PCR - Advantages and Disadvantages3.4 Different Types of PCR3.4.1 Simple Changes3.4.1.1 Multiplex-PCR3.4.1.2 VNTR PCR3.4.1.3 Asymmetric PCR3.4.1.4 Long PCR3.4.1.5 Nested PCR3.4.1.6 Quantitative PCR3.4.1.7 Hot-start PCR3.4.1.8 Touchdown PCR3.4.1.9 Assembly PCR3.4.1.10 Colony PCR3.4.1.11 Suicide PCR3.4.1.12 Cold PCR3.4.2 Digital PCR3.4.2.1 Droplet Digital PCR3.4.2.2 Comparison between dPCR and Real-Time PCR (qPCR)3.4.2.3 Digital PCR in Use3.4.2.4 Digital PCR Commercial History3.4.3 Isothermal PCR 4 Industry Overview4.1 Players in a Dynamic Market4.1.1 Academic Research Lab4.1.2 Diagnostic Test Developer4.1.3 Instrumentation Supplier4.1.4 Chemical/Reagent Supplier4.1.5 Pathology Supplier4.1.6 Independent Clinical Laboratory4.1.7 Public National/regional Laboratory4.1.8 Hospital Laboratory4.1.9 Physicians Office Lab (POLS)4.1.10 Audit Body4.1.11 Certification Body 5 Market Trends5.1 Factors Driving Growth5.1.1 A New Standard5.1.2 Down the Curve We Go5.1.3 Multiplexing5.1.4 Syndromic Diagnostics Looks Unstoppable5.1.5 The Genetic Blizzard5.2 Factors Limiting Growth5.2.1 The Cost Curve5.2.2 The Other Guys5.2.3 Systemic Roadblocks5.3 Diagnostic Technology Development5.3.1 The Instrumentation Curve5.3.2 Shifting Role of Diagnostics5.3.3 Diagnostics Moves Out of the Hospital5.3.4 Disruption Looms5.3.5 The Next Five Years 6 PCR Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Seegene, Microsoft Collaborate for MDx Development6.3 QuidelOrtho Expanding Savanna Test Menu6.4 Binx Health Refocuses on POC STI Testing6.5 Qiagen, Myriad Genetics Partner to Develop Cancer Dx6.6 VedaBio Detecting Nucleic Acid With CRISPR6.7 Evvy Launches Add-on STI Screen6.8 ChromaCode Shifts to Oncology with dPCR Lung Cancer Test6.9 Multiplex Meningitis/Encephalitis Panel Market Expanding6.10 Sensible Dx to Launch 10-Minute POC PCR System6.11 ReadyGo Dx Plans to Make MDx Testing Easy6.12 Transformative Biotech Acquires Summit Biolabs' PCR Tech6.13 Visby Medical POC STI Multiplex Test Cleared6.14 Sherlock Biosciences Buys Sense Biodetection6.15 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx6.16 HealthTrackRx Investing in Rapid Turnaround Times6.17 LEX Dx Developing Ultra-Fast Low-Cost PCR6.18 Next-Gen Dx Technologies Face Uncertain Future6.19 Rover Dx Developing All-Optical Rapid POC qPCR Platform6.20 ProtonDx Plans Rapid Molecular Dx Instrument6.21 Innova Medical Group Licenses MDx Tech6.22 MicroGEM to Grow Market for 30-Minute RT-PCR System6.23 Precipio Receives CE-IVD Mark for Cancer Panels6.24 Siemens Healthineers to Develop Next-Gen MDx Platform6.25 New York State Approves Enzo Biochem HPV Molecular Test6.26 Grip Molecular Developing Biosensor Panel to Detect Respiratory Infections6.27 Co-Diagnostics Seeks EUA for At-Home PCR Diagnostic System6.28 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing6.29 Finnish Firms to Form Point-of-Care Testing Firm6.30 Visby Medical Scales Up Handheld PCR Test for STIs6.31 DnaNudge Raises $60M6.32 Roche Reports Diagnostics Revenue Up 51 Percent6.33 BforCure Preparing Multiple ID Panels for PoC qPCR Platform6.34 Enzo Biochem, CLX Health Partner for C19 Testing for Travel6.35 Bio Molecular Systems Gets Approval for Portable PCR Cycler6.36 Roche Acquires GenMark6.37 Handheld qPCR Devices Close to Commercialization6.38 Nuclein Closes $14M in Funding6.39 WuXi Diagnostics Closes $150M Series B Financing Round6.40 Visby Medical to develop rapid Flu-COVID PCR test6.41 Thermo Fisher to Acquire Mesa Biotech 7 Profiles of Key PCR Companies7.1 Abbott Laboratories7.2 Accelerate Diagnostics7.3 Ador Diagnostics7.4 ADT Biotech7.5 Agilent7.6 Akonni Biosystems7.7 Altona Diagnostics7.8 Alveo Technologies7.9 Amoy Diagnostics Co., Ltd.7.10 Anatolia Geneworks7.11 Applied BioCode7.12 Applied DNA Sciences7.13 Aurora Biomed7.14 Aus Diagnostics7.15 AVIVA Systems Biology7.16 Beckman Coulter Diagnostics (Danaher)7.17 Becton, Dickinson and Company7.18 Binx Health7.19 Biocartis7.20 bioMerieux Diagnostics7.21 Bioneer Corporation7.22 Bio-Rad Laboratories, Inc7.23 Bosch Healthcare Solutions GmbH7.24 Bruker7.25 Caris Molecular Diagnostics7.26 Cepheid (Danaher)7.27 Credo Diagnostics Biomedical7.28 CTK Biotech7.29 Cue Health7.30 Curetis (OpGen)7.31 Diagenode Diagnostics (Hologic)7.32 Diasorin S.p.A.7.33 Eiken Chemical7.34 Enzo Biochem7.35 Eurofins Scientific7.36 Fluxergy7.37 Fujirebio7.38 Genetic Signatures7.39 GenMark Dx (Roche)7.40 Greiner Bio-One7.41 Hologic7.42 Immunexpress7.43 Inflammatix7.44 Invetech7.45 J&J Innovative Medicine7.46 Karius7.47 LumiraDx7.48 Maxim Biomedical7.49 Meridian Bioscience7.50 Millipore Sigma7.51 Molbio Diagnostics7.52 Nanomix7.53 NGeneBio7.54 Novacyt7.55 Nuclein7.56 Operon7.57 Panagene7.58 Precipio7.59 Primerdesign (Novacyt)7.60 Promega7.61 Prominex7.62 Qiagen7.63 QuantuMDx7.64 QuidelOrtho7.65 Randox Toxicology7.66 R-Biopharm AG7.67 Revvity7.68 Roche Diagnostics7.69 Scope Fluidics7.70 SD Biosensor7.71 Seegene7.72 Siemens Healthineers7.73 SkylineDx7.74 Sona Nanotech7.75 SpeeDx7.76 Standard BioTools7.77 Stilla Technologies7.78 Streamline Scientific7.79 T2 Biosystems7.80 Thermo Fisher Scientific7.81 Uniogen7.82 Vela Diagnostics7.83 Veramarx7.84 Veredus Laboratories7.85 Vircell7.86 Visby Medical7.87 XCR Diagnostics7.88 YD Diagnostics7.89 Zhejiang Orient Gene Biotech 8 The Global PCR Markets8.1 PCR - Global Market Overview by Country8.2 Global Market by Application - Overview8.3 Global Market by Technology - Overview8.4 Global Market by Product - Overview8.5 Global Market by Place - Overview 9 Global PCR Markets - By Application9.1 PCR Clinical Multiplex9.2 PCR Clinical Singleplex9.3 PCR Research 10 Global PCR Markets - By Technology10.1 qPCR10.2 dPCR 11 Global PCR Markets - By Product11.1 PCR Instruments11.2 PCR Nucleic Acid Extraction11.3 PCR Consumables11.4 PCR Services 12 Global PCR Markets - By Place12.1 PCR Clinical Laboratory12.2 PCR Point of Care12.3 PCR Commercial12.4 PCR Pharmaceutical 13 Appendices13.1 Growth of Approved IVD Test Menu13.2 Growth of Approved Average IVD Test Fee13.3 The Most Used IVD Assays13.4 The Highest Grossing Assays13.5 Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
36 minutes ago
- Yahoo
Uncovering UK Penny Stocks: Devolver Digital And 2 Other Top Contenders
The UK stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices slipping due to weak trade data from China, impacting companies closely tied to its economic fortunes. Despite these broader market concerns, penny stocks remain an intriguing area of exploration for investors. While the term "penny stocks" may seem outdated, these often smaller or newer companies can offer growth potential at lower price points when supported by strong financials and solid fundamentals. Name Share Price Market Cap Financial Health Rating Foresight Group Holdings (LSE:FSG) £4.12 £463.53M ★★★★★★ Stelrad Group (LSE:SRAD) £1.46 £185.93M ★★★★★☆ Cairn Homes (LSE:CRN) £1.846 £1.15B ★★★★★☆ Ultimate Products (LSE:ULTP) £0.746 £62.8M ★★★★★☆ Van Elle Holdings (AIM:VANL) £0.38 £41.12M ★★★★★★ Polar Capital Holdings (AIM:POLR) £4.50 £433.86M ★★★★★★ LSL Property Services (LSE:LSL) £2.90 £299.56M ★★★★★☆ Begbies Traynor Group (AIM:BEG) £1.065 £169.9M ★★★★★★ Croma Security Solutions Group (AIM:CSSG) £0.86 £11.84M ★★★★★★ Braemar (LSE:BMS) £2.31 £72.27M ★★★★★★ Click here to see the full list of 407 stocks from our UK Penny Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Devolver Digital, Inc. is a video game developer and publisher operating across multiple platforms globally, with a market cap of £106.76 million. Operations: The company generates revenue primarily from its Computer Graphics segment, totaling $104.78 million. Market Cap: £106.76M Devolver Digital, Inc., a video game developer and publisher with a market cap of £106.76 million, has demonstrated resilience despite being unprofitable. The company reported revenue of US$104.78 million for 2024, up from US$92.36 million the previous year, while reducing its net loss to US$6.14 million from US$12.74 million. Devolver remains debt-free and possesses sufficient cash runway for over three years based on current free cash flow levels, indicating financial stability in the short term despite ongoing losses and negative return on equity (-3.85%). Earnings are forecasted to grow significantly at 106% annually moving forward. Navigate through the intricacies of Devolver Digital with our comprehensive balance sheet health report here. Gain insights into Devolver Digital's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★★★ Overview: RWS Holdings plc offers technology-enabled language, content, and intellectual property services globally, with a market capitalization of £330.95 million. Operations: The company's revenue is derived from four main segments: IP Services (£102.3 million), Language Services (£327.1 million), Regulated Industry (£146.5 million), and Language & Content Technology (£142.3 million). Market Cap: £330.95M RWS Holdings, with a market cap of £330.95 million, has become profitable in the past year despite facing challenges such as an inexperienced management team and board. The company's diverse revenue streams include IP Services (£102.3M) and Language Services (£327.1M), among others. However, earnings are expected to decline by 10.9% annually over the next three years, and its dividend yield of 13.91% is not well supported by earnings or free cash flow. Recent executive appointments aim to drive growth and innovation, while RWS's debt is well covered by operating cash flow (101%). Jump into the full analysis health report here for a deeper understanding of RWS Holdings. Learn about RWS Holdings' future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Pensana Plc focuses on the exploration and development of mineral properties in the United Kingdom and Angola, with a market cap of £161.68 million. Operations: Currently, there are no revenue segments reported for the company. Market Cap: £161.68M Pensana Plc, with a market cap of £161.68 million, is pre-revenue and focuses on mineral exploration in the UK and Angola. Recent developments include a £2 million follow-on equity offering and an updated ore reserve estimate for its Longonjo project, which positions it as one of the largest undeveloped magnet metal projects globally. Despite being unprofitable, Pensana has reduced losses over five years and maintains a satisfactory net debt to equity ratio of 31.8%. The company has secured significant financing commitments totaling US$267.9 million to support its ambitious project plans but faces high share price volatility. Click here and access our complete financial health analysis report to understand the dynamics of Pensana. Gain insights into Pensana's historical outcomes by reviewing our past performance report. Take a closer look at our UK Penny Stocks list of 407 companies by clicking here. Looking For Alternative Opportunities? These 18 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIM:DEVO AIM:RWS and LSE:PRE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
